These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 31592732)

  • 1. MRI Atlas of IDH Wild-Type Supratentorial Glioblastoma: Probabilistic Maps of Phenotype, Management, and Outcomes.
    Roux A; Roca P; Edjlali M; Sato K; Zanello M; Dezamis E; Gori P; Lion S; Fleury A; Dhermain F; Meder JF; Chrétien F; Lechapt E; Varlet P; Oppenheim C; Pallud J
    Radiology; 2019 Dec; 293(3):633-643. PubMed ID: 31592732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Levetiracetam Use Duration on Overall Survival of Isocitrate Dehydrogenase Wild-Type Glioblastoma in Adults: An Observational Study.
    Pallud J; Huberfeld G; Dezamis E; Peeters S; Moiraghi A; Gavaret M; Guinard E; Dhermain F; Varlet P; Oppenheim C; Chrétien F; Roux A; Zanello M
    Neurology; 2022 Jan; 98(2):e125-e140. PubMed ID: 34675100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma.
    Molinaro AM; Hervey-Jumper S; Morshed RA; Young J; Han SJ; Chunduru P; Zhang Y; Phillips JJ; Shai A; Lafontaine M; Crane J; Chandra A; Flanigan P; Jahangiri A; Cioffi G; Ostrom Q; Anderson JE; Badve C; Barnholtz-Sloan J; Sloan AE; Erickson BJ; Decker PA; Kosel ML; LaChance D; Eckel-Passow J; Jenkins R; Villanueva-Meyer J; Rice T; Wrensch M; Wiencke JK; Oberheim Bush NA; Taylor J; Butowski N; Prados M; Clarke J; Chang S; Chang E; Aghi M; Theodosopoulos P; McDermott M; Berger MS
    JAMA Oncol; 2020 Apr; 6(4):495-503. PubMed ID: 32027343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Less Invasive Phenotype Found in Isocitrate Dehydrogenase-mutated Glioblastomas than in Isocitrate Dehydrogenase Wild-Type Glioblastomas: A Diffusion-Tensor Imaging Study.
    Price SJ; Allinson K; Liu H; Boonzaier NR; Yan JL; Lupson VC; Larkin TJ
    Radiology; 2017 Apr; 283(1):215-221. PubMed ID: 27849434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
    Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H
    J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive prediction of p53 and Ki-67 labelling indices and O-6-methylguanine-DNA methyltransferase promoter methylation status in adult patients with isocitrate dehydrogenase wild-type glioblastomas using diffusion-weighted imaging and dynamic susceptibility contrast-enhanced perfusion-weighted imaging combined with conventional MRI.
    Xing Z; Huang W; Su Y; Yang X; Zhou X; Cao D
    Clin Radiol; 2022 Aug; 77(8):e576-e584. PubMed ID: 35469666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of Core Signaling Pathway by Using Diffusion- and Perfusion-based MRI Radiomics and Next-generation Sequencing in Isocitrate Dehydrogenase Wild-type Glioblastoma.
    Park JE; Kim HS; Park SY; Nam SJ; Chun SM; Jo Y; Kim JH
    Radiology; 2020 Feb; 294(2):388-397. PubMed ID: 31845844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma.
    Vivas-Buitrago T; Domingo RA; Tripathi S; De Biase G; Brown D; Akinduro OO; Ramos-Fresnedo A; Sabsevitz DS; Bendok BR; Sherman W; Parney IF; Jentoft ME; Middlebrooks EH; Meyer FB; Chaichana KL; Quinones-Hinojosa A
    J Neurosurg; 2022 Jan; 136(1):1-8. PubMed ID: 34087795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. False-Positive Measurement at 2-Hydroxyglutarate MR Spectroscopy in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Multifactorial Analysis.
    Suh CH; Kim HS; Paik W; Choi C; Ryu KH; Kim D; Woo DC; Park JE; Jung SC; Choi CG; Kim SJ
    Radiology; 2019 Jun; 291(3):752-762. PubMed ID: 30990380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation Between Tumor Location and Clinical Properties of Glioblastomas in Frontal and Temporal Lobes.
    Li HY; Sun CR; He M; Yin LC; Du HG; Zhang JM
    World Neurosurg; 2018 Apr; 112():e407-e414. PubMed ID: 29355809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of O(6)-methylguanine-DNA methyltransferase promoter methylation status in IDH-wildtype glioblastoma using MRI histogram analysis.
    Liu X; Han T; Wang Y; Liu H; Zhou J
    Neurosurg Rev; 2024 Jun; 47(1):285. PubMed ID: 38907038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDH genotypes differentiation in glioblastomas using DWI and DSC-PWI in the enhancing and peri-enhancing region.
    Xing Z; Zhang H; She D; Lin Y; Zhou X; Zeng Z; Cao D
    Acta Radiol; 2019 Dec; 60(12):1663-1672. PubMed ID: 31084193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiomic MRI Phenotyping of Glioblastoma: Improving Survival Prediction.
    Bae S; Choi YS; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
    Radiology; 2018 Dec; 289(3):797-806. PubMed ID: 30277442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluid attenuation in non-contrast-enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma.
    Patel SH; Batchala PP; Muttikkal TJE; Ferrante SS; Patrie JT; Fadul CE; Schiff D; Lopes MB; Jain R
    J Neurooncol; 2021 May; 152(3):523-531. PubMed ID: 33661425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive influence of partial resection on overall survival of patients with overlapping glioblastomas.
    Quick-Weller J; Tritt S; Baumgarten P; Konczalla J; Kashefiolasl S; Noack A; Tichy J; Seifert V; Marquardt G
    Clin Neurol Neurosurg; 2017 Oct; 161():22-28. PubMed ID: 28837843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and Prognosis of Tumor-Related Epilepsy During Tumor Evolution in Patients With
    Pallud J; Roux A; Moiraghi A; Aboubakr O; Elia A; Guinard E; Oppenheim C; Tauziede-Espariat A; Parraga E; Gavaret M; Chrètien F; Huberfeld G; Zanello M
    Neurology; 2024 Jan; 102(1):e207902. PubMed ID: 38165369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of removed tumor volume and location on patient outcome in glioblastoma.
    Awad AW; Karsy M; Sanai N; Spetzler R; Zhang Y; Xu Y; Mahan MA
    J Neurooncol; 2017 Oct; 135(1):161-171. PubMed ID: 28685405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastoma.
    Seyve A; Lozano-Sanchez F; Thomas A; Mathon B; Tran S; Mokhtari K; Giry M; Marie Y; Capelle L; Peyre M; Carpentier A; Feuvret L; Sanson M; Hoang-Xuan K; Honnorat J; Delattre JY; Ducray F; Idbaih A
    Clin Neurol Neurosurg; 2020 Sep; 196():106006. PubMed ID: 32554237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma: a novel diagnostic and specific prognostic indicator.
    Kolakshyapati M; Adhikari RB; Karlowee V; Takayasu T; Nosaka R; Amatya VJ; Takeshima Y; Akiyama Y; Sugiyama K; Kurisu K; Yamasaki F
    J Neurosurg; 2018 Mar; 128(3):667-678. PubMed ID: 28362236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma.
    Yamashita K; Hatae R; Hiwatashi A; Togao O; Kikuchi K; Momosaka D; Yamashita Y; Kuga D; Hata N; Yoshimoto K; Suzuki SO; Iwaki T; Iihara K; Honda H
    Diagn Interv Imaging; 2019; 100(7-8):411-419. PubMed ID: 30948344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.